摘要
目的：探讨小剂量米非司酮对子宫肌瘤及其雌、孕激素受体（ＥＲ和ＰＲ）的影响。方法：服用米非司酮每日１０ｍｇ，治疗有症状的子宫肌瘤患者２７例，连续３个月后，其中７例行子宫切除，测其血清Ｅ２、Ｐ、ＦＳＨ、ＬＨ水平，并分别对子宫肌瘤及肌层组织用免疫组化方法测ＥＲ和ＰＲ；同时与未用药而行子宫切除的肌瘤进行比较。结果：每日服用１０ｍｇ米非司酮３个月后，使子宫肌瘤体积缩小４１．６％。体内的Ｅ２和Ｐ水平均下降，Ｅ２维持在滤泡早期水平；肌瘤的ＰＲ和ＥＲ含量均减少，ＰＲ减少更明显，接近绝经后水平。结论：小剂量米非司酮缩小子宫肌瘤的机理可能与其降低体内Ｅ２和Ｐ水平及肌瘤的ＰＲ和ＥＲ含量有关。
Objective: To examine the uterine leiomyomata and estrogen and progesterone receptors in response to low dose mifepristone administration. Methods:Administration of mifepristone 10 mg/d for a period of 3 months was conducted in 27 patients with symptomatic uterine leiomyomata. Ultrasound examinations were obtained before and after therapy as a measure of uterine and leiomyomata volume. Serum E2、P、FSH、LH were determined by radioimmunoassay in 7 hysterectomy cases. Leiomyomata and myometrial samples were obtained for immunocytochemical ER and PR levels and scored semiquantitatively and compared with those of mifepristone unusers. Results: Leiomyomata volume decreased 41.6%(P<0.01) after 3 months of therapy compared with pretreatment. Amenorrhea was induced and all anemia corrected. Serum E2 and P were reduced, serum E2 remained in early follicular phase; ER and PR in leiomyomata and myometrium, especially PR in leiomyomata were significantly reduced. Conclusion:Administration of low dose mifepristone (10 mg/d) for 3 months can reduce leiomyomata effectively. The mechanism may be because mifepristone reduces serum E2 and P as well as ER and PR in myometrium and leiomyomata.
出处
《北京医科大学学报》
CSCD
1998年第1期67-69,共3页
Journal of Peking University(Health Sciences)
关键词
米非司酮
子宫肿瘤
子宫肌瘤
雌激素
孕激素
Mifepristone/pharmacol Uterine neoplasms Receptors, estrogen/drug eff Receptor, progesterone/drug eff
